GlycoMimetics (GLYC)
(Delayed Data from NSDQ)
$0.26 USD
0.00 (-1.11%)
Updated Jun 7, 2024 04:00 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Brokerage Reports
GlycoMimetics, Inc. [GLYC]
Reports for Purchase
Showing records 21 - 40 ( 158 total )
Company: GlycoMimetics, Inc.
Industry: Medical - Drugs
1Q2022 Update - Still a Great Buy and a Strong M&A Target - $15 PT
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: GlycoMimetics, Inc.
Industry: Medical - Drugs
Company: GlycoMimetics, Inc.
Industry: Medical - Drugs
Key Takeaways from Panels & Fireside Chats at Our 34th Annual ROTH Conference
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: GlycoMimetics, Inc.
Industry: Medical - Drugs
Company: GlycoMimetics, Inc.
Industry: Medical - Drugs
4Q21 Results; Uproleselan Phase 3 Trial Data Expected After YE22
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: GlycoMimetics, Inc.
Industry: Medical - Drugs
4Q2021 Update - Progressing as Planned and We Remain Bullish, $15 PT
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: GlycoMimetics, Inc.
Industry: Medical - Drugs
Company: GlycoMimetics, Inc.
Industry: Medical - Drugs
Phase 2/3 AML Study Enrollment Completed With Data Likely in 2022
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: GlycoMimetics, Inc.
Industry: Medical - Drugs
Phase 2 Portion of NCI-Sponsored Trial of Uproleselan in Older, Newly Diagnosed AML Patients Achieves Full Enrollment
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: GlycoMimetics, Inc.
Industry: Medical - Drugs
Company: GlycoMimetics, Inc.
Industry: Medical - Drugs
Enrollment Completed for Pivotal Phase 3 study of Uproleselan in r/r AML
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: GlycoMimetics, Inc.
Industry: Medical - Drugs
Phase 3 Trial Evaluating Uproleselan in R/R AML Patients Completes Enrollment
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: GlycoMimetics, Inc.
Industry: Medical - Drugs
Company: GlycoMimetics, Inc.
Industry: Medical - Drugs
3Q21 Update: New CEO Reaffirms Strategy & Hints at a Catalyst-Rich 2022
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: GlycoMimetics, Inc.
Industry: Medical - Drugs
3Q21 Results; Uproleselan Trials Nearing Full Enrollment With Data Expected After YE22
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: GlycoMimetics, Inc.
Industry: Medical - Drugs
Company: GlycoMimetics, Inc.
Industry: Medical - Drugs
Takeaways from Our Call With Apollomics; Upro is Swiftly Advancing in China
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: GlycoMimetics, Inc.
Industry: Medical - Drugs
Reminder to Join Our Call Today On Upro''s Development in China
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z